High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later | Journal of Clinical Oncology
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | NEJM
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
Complications of high-dose Melphalan. | Download Table
Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial | Bone Marrow Transplantation
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | NEJM
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma | Bone Marrow Transplantation
Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma | Bone Marrow Transplantation
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | NEJM
A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple Myeloma - Biology of Blood and Marrow Transplantation
Hematopoietic recovery after high-dose melphalan and PBPC rescue | Download Table
Algorithm for patient selection and treatment with high-dose melphalan... | Download Scientific Diagram
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115 | Bone Marrow Transplantation
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma | Haematologica
Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation - Biology of Blood and Marrow Transplantation
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma - Clinical Lymphoma, Myeloma and Leukemia
Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma - Biology of Blood and Marrow Transplantation
High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease - Kidney International
Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis | Bone Marrow Transplantation
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. | Semantic Scholar
